

Innovation all for the patients



Roche A member of the Roche group

Galderma Announces Nemolizumab Data at American Academy of Dermatology (AAD) Annual Meeting

TOKYO, March 11, 2024 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that [Galderma](#) issued a press release regarding presentation of the results up to 52 weeks from an interim analysis of the OLYMPIA open-label extension study of nemolizumab in patients with prurigo nodularis, and results from an analysis of two phase III studies (ARCADIA 1 and ARCADIA 2) of nemolizumab at 48 weeks in patients with moderate to severe atopic dermatitis, at American Academy of Dermatology (AAD) Annual Meeting. Nemolizumab is a humanized anti-human IL-31 receptor A monoclonal antibody created by Chugai. Clinical development of nemolizumab outside Japan is being conducted by Galderma.

Galderma @ AAD 2024: new data demonstrate the long-term efficacy of nemolizumab in prurigo nodularis and its durability in atopic dermatitis

<https://www.galderma.com/news/galderma-aad-2024-new-data-demonstrate-long-term-efficacy-nemolizumab-prurigo-nodularis-and>

###